Investing.com - Sonnet Biotherapeutics Holdings reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Sonnet Biotherapeutics Holdings announced earnings per share of $-1.5100 on revenue of $100K. Analysts polled by Investing.com anticipated EPS of $-1.5400 on revenue of $50K.
Sonnet Biotherapeutics Holdings shares are down 82% from the beginning of the year , still down 89.33% from its 52 week high of $9.37 set on Wednesday, March 16, 2022.
Sonnet Biotherapeutics Holdings follows other major Healthcare sector earnings this month
Sonnet Biotherapeutics Holdings's report follows an earnings beat by Novo Nordisk ADR on Wednesday, November 2, 2022, who reported EPS of $0.8409 on revenue of $6.04B, compared to forecasts EPS of $0.837 on revenue of $6.04B.
AstraZeneca ADR had beat expectations on Thursday, November 10, 2022 with third quarter EPS of $1.67 on revenue of $10.98B, compared to forecast for EPS of $0.77 on revenue of $10.78B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar